Main Conference Day One (April 28, 2027) - CET/CEST (Cent Europe Summer, GMT+2)
- Bharat Dixit - Chief Technology Officer, ClearB Therapeutics
The Decision You Rarely Revisit—but Always Pay For
- Denes Zalai - Director Technology, Eleva Biologics
- Rosario Ramona Martínez García - Head of Process Technologist Group, Plant 1, Molecular Immunology Center (CIM)
Designing analytical approaches to characterise and quantify product variants and impurities.
Setting realistic acceptance criteria for impurities in complex molecules
Linking analytical impurity directly to functional biological activity and potency.
Launching a new innovative solution or looking to drive the conversation? Your expertise belongs on the stage. This high-impact slot is available to showcase late-breaking data, new platform capabilities, or expert case studies to our delegation. Reach out to Partners@informaconnectls.com to get involved!
- Kat Kozyrytska - Founder, Cell Therapy Manufacturability Program
Structuring regulatory packages for accelerated approval pathways across ADCs, radiotherapies, and complex formats.
Developing holistic control strategies and resolving regulatory roadblocks during late-stage filings.
Translating technical risk evaluations into actionable strategies that satisfy FDA/EMA expectations.
Launching a new innovative solution or looking to drive the conversation? Your expertise belongs on the stage. This high-impact slot is available to showcase late-breaking data, new platform capabilities, or expert case studies to our delegation. Reach out to Partners@informaconnectls.com to get involved!